Abstract

http://ssrn.com/abstract=1950943
 
 

References (56)



 
 

Citations (3)



 
 

Footnotes (18)



 


 



When Do Generics Challenge Drug Patents?


C. Scott Hemphill


Columbia University - Law School

Bhaven N. Sampat


Columbia University - Mailman School of Public Health

December 2011

Journal of Empirical Legal Studies, Vol. 8, Issue 4, pp. 613-649, 2011

Abstract:     
The Hatch‐Waxman Act regulates competition between brand‐name and generic drugs in the United States. We examine a feature of the Act that has attracted great controversy but little systematic attention. “Paragraph IV” challenges are a mechanism for generic drug makers to challenge the patents of brand‐name drug makers as a means to secure early market entry. We first present descriptive results that chart the rise of brand‐name patent portfolios and Paragraph IV challenges. Over time, patenting has increased, measured by the number of patents per drug and the length of the nominal patent term. Meanwhile, the fraction of drugs subjected to patent challenges has increased. Drugs are also challenged sooner, relative to brand‐name approval. Our econometric analyses of challenges over the past decade show that brand‐name sales have a positive effect on the likelihood of generic challenge. The likelihood of challenge also varies with the nature of the patent portfolio. A drug with weaker patents faces a significantly higher likelihood of challenge, conditional on sales and other drug characteristics. That is not because the drug's patent protection is weaker overall; additional patents, even weak ones, generally strengthen a brand‐name firm's ability to exclude. Rather, a weak patent, particularly if it expires later than the basic patents, disproportionately attracts a challenge to the pertinent drug. Overall, our results suggest these challenges serve a useful purpose by promoting scrutiny of weaker and late‐expiring patents.

Number of Pages in PDF File: 37

Accepted Paper Series





Date posted: October 29, 2011  

Suggested Citation

Hemphill, C. Scott and Sampat, Bhaven N., When Do Generics Challenge Drug Patents? (December 2011). Journal of Empirical Legal Studies, Vol. 8, Issue 4, pp. 613-649, 2011. Available at SSRN: http://ssrn.com/abstract=1950943 or http://dx.doi.org/10.1111/j.1740-1461.2011.01235.x

Contact Information

C. Scott Hemphill (Contact Author)
Columbia University - Law School ( email )
435 West 116th Street
New York, NY 10025
United States
Bhaven N. Sampat
Columbia University - Mailman School of Public Health ( email )
600 West 168th St. 6th Floor
New York, NY 10032
United States
Feedback to SSRN


Paper statistics
Abstract Views: 355
Downloads: 3
References:  56
Citations:  3
Footnotes:  18

© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollo3 in 0.531 seconds